New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:15 EDTXON, ZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
News For ZIOP;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
10:54 EDTZIOPZiopharm February volatility elevated at 135
Subscribe for More Information
January 26, 2015
08:34 EDTXONIntrexon launches tender offer to acquire stake in Exemplar Genetics
Subscribe for More Information
January 22, 2015
07:27 EDTXONIntrexon 3.75M share Secondary priced at $27.00
The deal size was reduced to $101M in common stock from $150M in common stock. JPMorgan and BofA/Merrill acted as joint book running managers for the offering.
January 20, 2015
16:03 EDTXONIntrexon files to sell $150M in common stock
Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments. J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. Jefferies is acting as a lead manager for the offering. Griffin Securities and Mizuho Securities are acting as co-managers for the offering.
13:21 EDTZIOP, XONCAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
05:54 EDTZIOPStocks with implied volatility movement; ZIOP INVN
Subscribe for More Information
January 16, 2015
10:14 EDTZIOPZiopharm mentioned cautiously by TheStreetSweeper blog
Subscribe for More Information
January 15, 2015
12:34 EDTXONIntrexon mentioned cautiously at White Diamond Research
Reference Link
January 14, 2015
16:33 EDTXON, ZIOPOn The Fly: Closing Wrap
Subscribe for More Information
12:49 EDTXON, ZIOPOn The Fly: Midday Wrap
Subscribe for More Information
10:10 EDTZIOPHigh option volume stocks
Subscribe for More Information
10:00 EDTZIOPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTXON, ZIOPOn The Fly: Pre-market Movers
HIGHER: ZIOPHARM (ZIOP), up 53% after the company and Intrexon (XON) announced a licensing agreement with University of Texas. Intrexon shares are also up 12%... GameStop (GME), up 10.6% after reporting holiday SSS, providing guidance for the fourth quarter and fiscal 2014, and being upgraded at Pacific Crest... Smith Micro (SMSI), up 12.7% after reporting preliminary fourth quarter revenue and providing revenue guidance for the first quarter and fiscal 2015... BioCryst (BCRX), up 3.2% after receiving a positive opinion on EMA orphan drug designation for BCX4161... GoPro (GPRO), up 1% following analyst remarks that sell-off after yesterday's report on Apple (AAPL) patent was "overdone." DOWN AFTER EARNINGS: JPMorgan (JPM), down 2.7%... Wells Fargo (WFC), down 2.2%... Banking peers down as well, with Bank of America (BAC) down 2.8% and Citi (C) down 2%. ALSO LOWER: Tesla (TSLA), down 9% following comments made by CEO Elon Musk at an automotive conference in Detroit regarding a slowdown in China... New Media (NEWM), down 4.8% after 7M share spot secondary priced at $21.70... General Motors (GM), down 3% after giving 2015 guidance, saying it is on track to meet previously announced 2016 financial targets... Apple (AAPL), down 1% following lawsuit against Ericsson (ERIC) and countersuit filing.
08:43 EDTZIOPZiopharm upgraded at BMO Capital
As noted earlier, BMO Capital upgraded Ziopharm (ZIOP) to Outperform from Market Perform. The firm believes that the company's licensing deal with MD Anderson for CAR-T cancer treatments , announced yesterday, will be "transformational" for Ziopharm. The firm is upbeat on the outlook for CAR-T technology. Target to $15 from $1.
08:23 EDTZIOPZiopharm upgraded to Outperform from Market Perform at BMO Capital
January 13, 2015
18:37 EDTZIOPOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTZIOP, XONIntrexon, Ziopharm announce licensing agreement with University of Texas
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use